Secondary Logo

Journal Logo

ARTICLE: STOMACH

Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study

Liu, Jing MD1,2,3; Ji, Chao-Ran MD1,2,3; Li, Yue-Yue MD1,2,3; Qiao, Chen MD1,2,3; Hu, Jun-Nan MD1,2,3; Wan, Meng BD1,2,3; Lin, Min-Juan BD1,2,3; Lin, Bo-Shen BD1,2,3; Wang, Juan BD1,2,3; Zha, Jing BD1,2,3; Li, Li-Xiang PhD1,2,3; Zuo, Xiu-Li MD, PhD1,2,3

Author Information
Clinical and Translational Gastroenterology: August 2021 - Volume 12 - Issue 8 - p e00391
doi: 10.14309/ctg.0000000000000391
  • Open

Abstract

INTRODUCTION

The global prevalence of Helicobacter pylori is approximately 40% (1). As a common pathogen leading to various gastrointestinal diseases, H. pylori eradication alleviates gastric atrophy and prevents metachronous gastric cancer (2–5). However, with increasing antibiotic resistance, H. pylori eradication has become a therapeutic challenge (6,7).

Currently, 14-day bismuth-containing quadruple therapies (BQTs) are recommended as the first-line therapeutic regimen in areas where antibiotic resistance is high (8–10). After BQT failure, fewer options of subsequent rescue regimens are available. Currently, traditional treatment regimens fail to achieve satisfactory cure rates (11). The posttreatment resistance rates of H. pylori to clarithromycin (58.3%), metronidazole (99.2%), and levofloxacin (52.3%) have increased significantly in China (12), reducing the efficacy of all non-BQTs. For this reason, in a certain proportion of patients, the infection cannot be eliminated after multiple rounds of treatment, and they are often left untreated because there are no other conventional options (13).

In clinical trials involving patients with refractory H. pylori infection, antimicrobial susceptibility-guided therapies failed to achieve satisfactory efficacies. We conducted a randomized controlled trial (RCT) for the second-line or third-line therapy of H. pylori to compare the efficacy of antimicrobial susceptibility-guided with empirical BQTs. The eradication rates in both groups were <80% in intention-to-treat (ITT) analysis (14). However, antimicrobial susceptibility testing is time-consuming, expensive, and has certain technical prerequisites.

A novel rescue regimen is urgently required to solve this therapeutic dilemma in China. The aim of this pilot study was to evaluate the efficacy and tolerability of 2 different 1-week quadruple therapies given back-to-back consecutive therapy in Chinese patients with difficult-to-treat H. pylori infection.

METHODS

Study design and participants

This pilot study was approved by the Ethics Committee of Qilu Hospital of Shandong University (number 2019186), and the Declaration of Helsinki was followed. All patients provided written informed consent before recruitment (Clinical Trials.gov, number NCT03658733).

Consecutive patients aged 18–70 years were eligible for this study if they were confirmed to have persistent H. pylori infection and had failed >3 rounds of standard quadruple regimens in previous eradication attempts. Before enrollment, H. pylori infection was diagnosed using at least 2 of the following tests: 13C‐urea breath test (13C‐UBT), histology, and rapid urease test. Exclusion criteria were as follows: (i) history of gastrectomy, acute gastrointestinal bleeding, or gastric malignancy; (ii) unclear previous eradication regimens; (iii) contraindication or allergy to any study drugs administered in the regimens; (iv) pregnancy or lactation; (v) severe concurrent diseases; (vi) alcohol abuse or drug addiction; (vii) use of proton pump inhibitors (PPIs), histamine-2 receptor antagonists, bismuth-containing drugs, or antibiotics in the preceding 4 weeks; (viii) unwillingness or intolerance to gastroscopy or H. pylori culture; (ix) compliance of <90% during any previous eradication; and (x) inability to sign informed consent.

Procedures

Patient demographics, characteristics, and previous eradication regimens were recorded at entry. Previous antibiotic use was defined as the continuous use of antibiotics whether oral or intravenous for >14 days for any reason besides H. pylori eradication. In addition, physical examinations, vital signs, hematology, serum chemistry, and electrocardiography were performed before gastroscopy. All patients underwent gastroscopy, H. pylori culture, and antimicrobial susceptibility testing before treatment.

H. pylori culture and antimicrobial susceptibility testing

At gastroscopy, 2 biopsy specimens were obtained from antrum and corpus for H. pylori culture. The specimens were maintained at −80 °C in brain-heart infusion broth (Oxoid, Basingstoke, UK) and then immediately sent to Zhiyuan Medical Inspection Institute (Hangzhou, Zhejiang, China). Specimens were fully ground and then cultured on brain-heart infusion agar medium (Oxoid, Basingstoke, UK) with 5% sheep blood at 37 °C under microaerophilic conditions (85% N2, 10% CO2, 5% O2) for 3–7 days. The H. pylori colonies were identified by Gram-negative staining and positivity for urease, cytochrome oxidase, and catalase activity.

Susceptibility to commonly used antibiotics against H. pylori was evaluated using the standard agar plate dilution method. After 72 hours of cultivation at 37 °C under microaerophilic conditions, the minimal inhibitory concentration was determined based on the lowest antibiotic concentration that inhibited visible bacterial growth. The reference strain ATCC43504 (NCTC11637) was included as a quality control. The minimal inhibitory concentrations of clarithromycin (1 μg/mL), metronidazole (8 μg/mL), amoxicillin (1 μg/mL), levofloxacin (1 μg/mL), furazolidone (1 μg/mL), and tetracycline (1 μg/mL) were in accordance with the criteria of the US Clinical and Laboratory Standards Institute.

Eradication therapy and follow-up

Patients were randomly assigned to receive either esomeprazole or rabeprazole in a ratio of 1:1 according to a predetermined random number sequence generated by a computer. All patients were administered consecutive therapy containing esomeprazole 40 mg/rabeprazole 20 mg, amoxicillin 1,000 mg, furazolidone 100 mg, and tetracycline 500 mg for the first 7 days, followed by colloidal bismuth pectin 200 mg in place of furazolidone for another 7 days. PPIs and colloidal bismuth pectin were administrated 30 minutes before breakfast and dinner; amoxicillin was administrated 30 minutes after breakfast and dinner; tetracycline was given 4 times daily (30 minutes after breakfast/lunch/dinner and before bed); and furazolidone 3 times daily (30 minutes after breakfast/lunch/dinner).

Before treatment, patients received both oral and written medical instructions, including detailed therapy regimens, possible treatment-emergent adverse events (TEAEs), and the importance of rational medication use. Patients who experienced discomforts were instructed to contact the investigators immediately. All patients were asked to return within 3 days of the end of treatment. Adherence and adverse symptoms were evaluated using their medication diaries and laboratory tests.

Outcomes

Eight weeks after completion of the regimen, H. pylori infection status was evaluated using 13C-UBT, whereas of histamine-2 blocker, PPIs, antimicrobials, and bismuth-containing drugs for at least 4 weeks. Successful H. pylori eradication was defined as a negative 13C-UBT result with a delta‐over‐baseline value of <0.4%. The primary endpoint was the H. pylori cure rate. The secondary outcomes were the rates of drug-related TEAEs, compliance, and resistance to antibiotics. Physical examinations, vital signs, hematology, and serum chemistry were performed after the treatment. TEAEs and concomitant medications were observed synchronously during therapeutic sessions. All TEAEs were coded and categorized (MedDRA v.19.0) for system organ class and preferred term among patients who received a minimum of 1 dose of the study drug. The relationships of the TEAEs to the study drugs were also recorded, as were their severity and the necessity of early treatment discontinuation. Low compliance was identified when <90% of the pills had been taken.

Statistical analysis

We assumed that the eradication rate of consecutive therapy was 88% (15). Given a 95% confidence interval of 79.8%–96.2%, a sample size of 61 patients was required. Assuming that 5% would be lost to follow-up, a minimum of 65 patients was required.

Continuous variables were described as mean ± SD, and percentages were calculated for categorical variables. The H. pylori eradication rates were calculated on an ITT basis and a per-protocol (PP) basis. All eligible patients were included in the ITT analysis. All protocol violators, for whom a posttreatment 13C‐UBT was unavailable, were excluded from PP analysis, as were those with low compliance. Data were analyzed using R software (version 3.6.0; R Foundation for Statistical Computing, Vienna, Austria).

This pilot study was approved by the Ethics Committee of Qilu Hospital of Shandong University (number 2019186).

RESULTS

Patients

The study flow is shown in Figure 1. From December 2018 to August 2020, 102 patients were screened for eligibility. Of these, 65 met the selection criteria and received consecutive treatments at Qilu Hospital of Shandong University. The demographic and clinical characteristics of the study population in the ITT analysis are listed in Table 1. On average, patients had undergone 3.6 previous H. pylori treatment courses (range 3–7). Among their medication histories, multiple antibiotics had previously been administered, including clarithromycin, amoxicillin, metronidazole, and levofloxacin. In total, 87.7% of the enrolled patients reported a previous history of furazolidone medication and 43.1% had a history of tetracycline medication. One patient withdrew from this study, and 2 patients discontinued treatment. One patient with poor compliance was excluded from PP analysis, despite a negative follow-up 13C-UBT.

Figure 1.
Figure 1.:
Consolidated standards of reporting trials flowchart of this study. ITT, intention-to-treat; PP, per-protocol.
Table 1. - Demographic and clinical characteristics of the enrolled patients
Characteristic Consecutive therapy (N = 65)
Age (yr; mean ± SD) 49.7 ± 8.8
Male 41 (63.1%)
Smokinga 5 (7.7%)
Drinkingb 9 (13.9%)
BMI, kg/m2, mean ± SD 23.3 ± 3.4
NSAID user 3 (4.6%)
Complication 7 (10.8%)
 Diabetes mellitus 4 (6.2%)
 Hypertension 5 (7.7%)
Endoscopic finding
 Atrophy gastritis 42 (64.6%)
 Peptic ulcer 4 (6.2%)
 Gastric intraepithelial neoplasia 3 (4.6%)
Familial history of gastric cancer 12 (18.5%)
Times of eradication failure
 3 37 (56.9%)
 4 18 (27.7%)
 ≥5 10 (15.4%)
Previous clarithromycin usec 65 (100%)
Previous amoxicillin usec 65 (100%)
Previous metronidazole usec 65 (100%)
Previous levofloxacin usec 65 (100%)
Previous furazolidone usec 57 (87.7%)
Previous tetracycline usec 28 (43.1%)
Clarithromycin resistanced 31 (60.8%)
Amoxicillin resistanced 1 (2.0%)
Metronidazole resistanced 51 (100%)
Levofloxacin resistanced 36 (70.6%)
Furazolidone resistanced 0
Tetracycline resistanced 0
BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug.
aAn individual who smoked more than 1 cigarette every day for more than 1 yr was considered as a smoker.
bAn individual who drank alcohol more than once per week for at least 12 mo was defined as a drinker.
cPrevious antibiotic use was identified in patients who had continuous antibiotics (oral or intravenous agents for ≥14 d) for any reason besides H. pylori eradication.
dStrains were isolated from 51 patients.

Eradication rates

Successful H. pylori eradication was confirmed in 59 patients. The overall eradication rates of consecutive therapy using ITT and PP analyses were 90.8% (59/65) and 95.1% (58/61), respectively. The eradication rates of esomeprazole-based and rabeprazole-based regimens were 90.6% (29/32) and 90.9% (30/33), respectively, using ITT analysis and 96.7% (29/30) and 93.6% (29/31) using PP analysis. The eradication rate was 92.2% (47/51) in H. pylori-isolated participants. The eradication rates based on the number of previous failed regimens are listed in Table 2. Notably, H. pylori strains from 28 patients were resistant to at least 3 commonly used antibiotics, and 92.9% of these patients achieved successful eradication. The eradication rates were similar between the fourth- and fifth-line attempts, and they were not decreased when the regimen was prescribed after 5 or more eradication failures.

Table 2. - Eradication rates of consecutive therapy according to previous regimen failures
Variable Overall eradication rates 4th-line ≥5th-line
ITT analysis 90.8% (59/65) 86.5% (32/37) 96.4% (27/28)
PP analysis 95.1% (58/61) 91.4% (32/35) 100% (26/26)
ITT, intention-to-treat; PP, per-protocol.

Adverse effects and compliance

In the safety analysis, the incidence of TEAEs was 39.1% (25/64), with 35.9% of patients (23/64) reporting only mild TEAEs and 3.1% (2/64) reporting TEAEs of moderate severity. No serious adverse events (SAEs) were observed. None of the patients received drug or nonpharmaceutical treatment for TEAEs. Two patients experienced TEAEs that led to study drug discontinuation, and they refused to undergo follow-up UBT; 1 patient had drug-related headache, dizziness, nausea, and vomiting on the ninth day of medications. The others reported headache, arthralgia, pyrexia, abdominal pain, diarrhea, nausea, and vomiting on day 2 after eating expired food and then was diagnosed with acute gastroenteritis by investigators, which was unrelated to the eradication therapy.

Overall, 23.4% (15/64) of patients reported drug-related TEAEs judged by investigators as having a reasonable suspected causal relationship to the study drug. Gastrointestinal disorders (nausea and abdominal pain) were the most common drug-related SOCs with an incidence of 14.1% (9/64). The incidences of drug-related TEAEs for the first week (furazolidone-based) and second week (bismuth-based) quadruple therapy were 15.6% (10/64) and 10.9% (7/64), respectively. All drug-related symptoms resolved spontaneously after treatment completion or premature drug cessation.

Regarding laboratory abnormalities, 2 patients showed mild liver function abnormality, which was caused by nonalcoholic fatty liver disease in 1 patient. A 46-year-old man had mild leukopenia (white cell count 2.1 × 109/L and neutrophils 1.3 × 109/L), which was considered to be related to esomeprazole. All TEAEs disappeared at the posttreatment week 4 visit, and no drug intervention was conducted. No clinically relevant changes were observed in electrocardiogram or vital signs.

Patients with good compliance accounted for 95.3% (61/64). An overview of TEAEs and compliance with consecutive therapy is listed in Table 3.

Table 3. - TEAEs and patient compliance with 14-day consecutive therapy
Variable Consecutive therapy
Total no. of TEAEs 41
No. of drug-related TEAEs 46.3% (19/41)
Mild 84.2% (16/19)
Moderate 15.8% (3/19)
Severe 0
Serious adverse events 0
No. of patients with TEAEs 39.1% (25/64)
No. of patients with drug-related TEAEs 23.4% (15/64)
Headache 3.1% (2/64)
Dizziness 1.6% (1/64)
Nausea 6.3% (4/64)
Abdominal pain 3.1% (2/64)
Diarrhea 3.1% (2/64)
Dyspepsia 3.1% (2/64)
Vomiting 1.6% (1/64)
Fatigue 1.6% (1/64)
Leukopenia 1.6% (1/64)
Eyelid edema 1.6% (1/64)
Vision blurred 1.6% (1/64)
AST increased 1.6% (1/64)
Dropout because of TEAEs 3.1% (2/64)
Drug-related dropout 1.6% (1/64)
Compliance 95.3% (61/64)
Compliance was indicative of patients taking at least 90% of the pills.
AST, aspartate aminotransferase; TEAE, treatment-emergent adverse event.

Susceptibility results

Overall, H. pylori were successfully isolated in 78.5% (51/65) of the patients. The resistance rates of H. pylori isolates toward clarithromycin, metronidazole, levofloxacin, and amoxicillin were 60.8% (31/51), 100% (51/51), 70.6% (36/51), and 2.0% (1/51), respectively. No resistance was detected to furazolidone or tetracycline (Table 1). The overall triple drug resistance rate (clarithromycin, metronidazole, and levofloxacin) was 54.9% (28/51) and further increased to 71.4% (5/7) among patients with 5 previous therapy failures.

DISCUSSION

Failure to cure H. pylori infection presents a difficult clinical therapeutic problem, especially in patients with precancerous lesions who have experienced several failed attempts with combined common antibiotics. In this pilot study, consecutive eradication therapy containing 3 antibiotics known to have the highest resistance barrier was developed to treat those who had experienced >3 previous eradication failures; the results showed that the regimen achieved good therapeutic efficacy (95.1% by PP and 90.8% by ITT), it was tolerable by most patients, and compliance was good in China. The incidence of drug-related TEAEs was similar to that of previously reported TEAEs (15,16).

Factors that may cause treatment failure include presence of multiple antibiotic resistance, inadequate suppression of gastric acid secretion, poor compliance, and inadequate therapy duration. The enrolled patients had already failed multiple quadruple eradication regimens involving key antibiotics. Moreover, 96.9% of patients (63/65) had received failed quadruple eradication with at least 2 low-resistance antibiotics, such as amoxicillin, furazolidone, and tetracycline. Of these, 14 patients (21.5%) have experienced failed regimens containing amoxicillin, tetracycline, and a PPI. In China, the resistant rates of H. pylori to amoxicillin, tetracycline, and furazolidone are lower than 5% (14,17), and reuse of these antibiotics rarely results in subsequent resistance. The consecutive regimen includes 3 antibiotics known to have the highest resistance barrier to achieve satisfactory efficacy in a difficult-to-treat group. In addition, 57 patients (87.7%) had received at least 1 failed eradication attempt containing amoxicillin 1,000 mg and furazolidone 100 mg twice daily. Regimens containing an increased dose of furazolidone (100 mg 3 or 4 times daily), based on previous data (18–20), could achieve satisfactory efficiency. This should be taken into account because the short duration of these treatments did not increase SAEs (21,22). Without increasing the total dose (<2.8 g), the daily dose of furazolidone was increased to 300 mg for 7 days in this study. Finally, amoxicillin 500 mg 4 times daily may further increase the eradication rate, although it may also lower patient compliance because it involves complex regimens. Consecutive therapy achieved a cure rate of 95.1% in the PP population, an encouraging result when considering that almost every patient received the same 2 low-resistance antibiotics previously used. This may be because no drug resistance was noted for these 3 antimicrobials. Moreover, the efficacy did not decrease with an increasing number of previous failures.

Previous studies have shown that double-dose esomeprazole regimens increase the efficacy of H. pylori eradication therapy (23,24). Esomeprazole-based and rabeprazole-based regimens have shown little difference in efficacy among different CYP2C19 genotypes and are recommended for rescue therapies in Asian populations (25–28). Thus, in this preliminary study, we selected esomeprazole 40 mg and rabeprazole 20 mg twice daily to obtain adequate acid suppression. However, as a novel potassium-competitive acid blocker, vonoprazan exhibits a more rapid, sustained, and profound acid-inhibitory effect compared with esomeprazole and rabeprazole in Japanese individuals, regardless of CYP2C19 polymorphisms. Further studies will undertake vonoprazan because of the established importance of acid suppression in improving the efficacy of amoxicillin against H. pylori.

The furazolidone-containing regimen showed no increased risk of drug-related TEAEs or SAEs compared with other antibiotic regimens, despite variable daily doses, medication duration, and regimen forms (29,30). Liang et al. (19) showed that the regimens containing 300 mg of furazolidone per day were well tolerated and achieved ≥90% cure rates. Severe TEAEs are more common in regimens containing high doses (≥200 mg twice daily) or long durations (>7 days). Tetracycline-containing and furazolidone-containing regimens may have good efficacy with only occasionally SAEs (31,32). The incidence of SAEs is rare (0.4‰), and penicillin allergy cannot be completely ruled out (30). Meanwhile, amoxicillin-based and furazolidone-based therapies have also demonstrated high cure rates with a favorable safety profile (19,33). Significantly, dual therapies including high doses of PPIs and amoxicillin have proven to be safe and effective (34,35). Our current findings showed that consecutive therapy was well tolerated in the study population. A similar incidence of drug-related TEAEs has been observed previously (15,31). One-week furazolidone quadruple therapy has a higher incidence of drug-related TEAEs probably because of the increased daily dose of furazolidone 300 mg. Notably, all adverse events were mild-to-moderate with a low occurrence of drug-related discontinuation. The most common drug-related TEAEs were nausea (6.3%), and similar results have been reported in previous studies.

Good compliance with treatment could improve the H. pylori cure rate (36,37). Despite the slightly complex regimen, good compliance was achieved in 95.3% of the patients, probably attributed to the detailed education by investigators, high motivation of patients, and exclusion of patients with poor compliance during previous therapies.

The success rate of H. pylori isolation (78.5%, 51/65) was not ideal. Previous studies found that patients with autoimmune gastritis are often misdiagnosed with false-positive results in 13C-UBT and rapid urease test because of the presence of other urease-containing bacteria (38–40). Furthermore, bacteria with structural similarity to H. pylori may led to the false-positive histology result (41). No patients with pernicious anemia were found in our study population. Antiparietal cell antibody and anti-intrinsic factor antibody tests were not performed, and prolonged transport may influence the optimal recovery of the organisms from gastric biopsy specimens. Finally, among patients with good compliance, the eradication rates were similar in the positive-culture and negative-culture groups (95.8% vs 92.3%).

There were some methodological weaknesses that may restrict the validity of our results. First, as this study was a single-arm pilot study, it was not possible to compare the eradication efficacy. The occurrence of drug-related TEAEs was similar between consecutive therapy in this study and bismuth-containing quadruple therapy in a previous study (15). Large-scale, multicenter RCTs must be conducted to confirm these results in regions with different patterns of resistance. Second, CYP2C19 polymorphisms were not tested before initiating treatment. Nevertheless, esomeprazole 40 mg or rabeprazole 20 mg twice daily was selected to ensure sufficient acid suppression because CYP2C19 has a minimal significant effect on the esomeprazole-based or rabeprazole-based therapies. However, it remains a major weakness of our study because both esomeprazole and rabeprazole were used simultaneously. Third, although drug-related TEAEs were carefully assessed, the dynamic changes of gut microbiota were not monitored while the relatively broad-spectrum antibiotics were used. It is still unknown whether this regimen affects the antimicrobial resistance of Escherichia coli and its metabolic parameters. Finally, tetracycline, furazolidone, and bismuth compounds are not always available in many areas. Considering the relatively low cost of these drugs, reasonable application of these drugs could effectively reduce the cost of eradication.

This pilot study showed that even after >previous H. pylori eradication failures in a specific population with high levels of multiple antimicrobial resistance, consecutive therapy including amoxicillin, tetracycline, and furazolidone, was feasible to achieve a good eradication rate (>90%) with acceptable tolerability and good compliance, regardless of a medication history of these 3 antibiotics. These findings should be further elucidated using multicenter RCTs for clinical application in Chinese patients.

CONFLICTS OF INTEREST

Guarantor of the article: Xiu-Li Zuo, MD, PhD.

Specific author contributions: Jing Liu, MD, and Chao-Ran Ji, MD, contributed equally to this work. J.L., C-R.J., and Y-Y.L.: research design and drafting of the article. C.Q., J-N.H., M.W., B-S.L., M-J.L., J.W., and J.Z.: data collection. J.L. and C-R.J.: analysis and interpretation of data. X-L.Z. provided critical revision of the article. All authors read and approved the final article.

Financial support: This investigation was funded by the National Natural Science Foundation of China (81770538, 81570485) and Key Research and Development Program of Shandong Province (2017CXGC1215). This work was independent of the funding.

Potential competing interests: None to report.

Institutions participating in the study: The endoscopy unit, Qilu Hospital of Shandong University, Jinan, China; Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, Jinan, China.

Trial identification number:ClinicalTrials.gov ID: NCT03658733, https://clinicaltrials.gov/ct2/show/NCT03658733

Study Highlights

WHAT IS KNOWN

  • ✓ The posttreatment resistance rates of Helicobacter pylori are increasing.
  • ✓ Traditional fourth-line regimens fail to achieve satisfactory cure rates of H. pylori infection.

WHAT IS NEW HERE

  • ✓ Consecutive therapy achieves a good cure rate in difficult-to-treat H. pylori infections.

REFERENCES

1. Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: The worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther 2018;47:868–76.
2. Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med 2020;382:427–36.
3. Chiang TH, Chang WJ, Chen SL, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: A long-term cohort study on Matsu Islands. Gut 2020;70:243–250.
4. Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018;378:1085–95.
5. Kim HJ, Kim YJ, Seo SI, et al. Impact of the timing of Helicobacter pylori eradication on the risk of development of metachronous lesions after treatment of early gastric cancer: A population-based cohort study. Gastrointest Endosc 2020;92:613–22.e1.
6. Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and meta-analysis in world health organization regions. Gastroenterology 2018;155:1372–82.e17.
7. Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology 2019;157:44–53.
8. Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol 2017;112:212–39.
9. Fallone CA, Chiba N, van Zanten SV, et al. The toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016;151:51–69.e14.
10. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/florence consensus report. Gut 2017;66:6–30.
11. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143–53.
12. Liu DS, Wang YH, Zhu ZH, et al. Characteristics of Helicobacter pylori antibiotic resistance: Data from 4 different populations. Antimicrob Resist Infect Control 2019;8:192–8.
13. Gisbert JP, Pajares JM. Review article: Helicobacter pylori “rescue” regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047–57.
14. Ji CR, Liu J, Li YY, et al. Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial. J Dig Dis 2020; 21:549–557.
15. Yang J, Zhang Y, Fan L, et al. Eradication efficacy of Modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori. Am J Gastroenterol 2019;114:437–45.
16. Gisbert JP, Castro-Fernandez M, Perez-Aisa A, et al. Fourth-line rescue therapy with rifabutin in patients with 3 Helicobacter pylori eradication failures. Aliment Pharmacol Ther 2012;35:941–7.
17. Zamani M, Rahbar A, Shokri-Shirvani J. Resistance of Helicobacter pylori to furazolidone and levofloxacin: A viewpoint. World J Gastroenterol 2017;23:6920–2.
18. Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: Lessons from China. Eur J Gastroenterol Hepatol 2013;25:1134–40.
19. Liang X, Xu X, Zheng Q, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013;11:802–7.e1.
20. Cheng H, Hu FL. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J Gastroenterol 2009;15:860–4.
21. Mohammadi M, Attaran B, Malekzadeh R, et al. Furazolidone, an underutilized drug for H. pylori eradication: Lessons from Iran. Dig Dis Sci 2017;62:1890–6.
22. Mokhtare M, Hosseini V, Tirgar Fakheri H, et al. Comparison of quadruple and triple Furazolidone containing regimens on eradication of Helicobacter pylori. Med J Islam Repub Iran 2015;29:195.
23. De Francesco V, Ridola L, Hassan C, et al. Two-week triple therapy with either standard or high-dose esomeprazole for first-line H. pylori eradication. J Gastrointestin Liver Dis 2016;25:147–50.
24. Graham DY, Lu H, Dore MP. Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter 2019;24:e12554.
25. McNicholl AG, Linares PM, Nyssen OP, et al. Meta-analysis: Esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012;36:414–25.
26. Wu IC, Wu DC, Hsu PI, et al. Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection. Helicobacter 2007;12:633–7.
27. Kuo CH, Wang SS, Hsu WH, et al. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter 2010;15:265–72.
28. Lima JJ, Thomas CD, Barbarino J, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther 2020;109:1417–1423.
29. Zhuge L, Wang Y, Wu S, et al. Furazolidone treatment for Helicobacter pylori infection: A systematic review and meta-analysis. Helicobacter 2018;23:e12468.
30. Ji CR, Liu J, Li YY, et al. Safety of furazolidone-containing regimen in Helicobacter pylori infection: A systematic review and meta-analysis. BMJ Open 2020;10:e037375.
31. Zhang Y, Gao W, Cheng H, et al. Tetracycline- and furazolidone-containing quadruple regimen as rescue treatment for Helicobacter pylori infection: A single center retrospective study. Helicobacter 2014;19:382–6.
32. Song C, Qian X, Zhu Y, et al. Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice. Helicobacter 2019;24:e12591.
33. Zhang YW, Hu WL, Cai Y, et al. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J Gastroenterol 2018;24:4596–605.
34. Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2015;13:895–905.e5.
35. Tai WC, Liang CM, Kuo CM, et al. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: A prospective randomized trial. J Antimicrob Chemother 2019;74:1718–24.
36. Al-Eidan FA, McElnay JC, Scott MG, et al. Management of Helicobacter pylori eradication-the influence of structured counselling and follow-up. Br J Clin Pharmacol 2002;53:163–71.
37. Wang T, Yang X, Li Y, et al. Twice daily short-message-based re-education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study. Helicobacter 2019;24:e12569.
38. Furuta T, Baba S, Yamade M, et al. High incidence of autoimmune gastritis in patients misdiagnosed with 2 or more failures of H. pylori eradication. Aliment Pharmacol Ther 2018;48:370–7.
39. Terao S, Suzuki S, Yaita H, et al. Multicenter study of autoimmune gastritis in Japan: Clinical and endoscopic characteristics. Dig Endosc 2020;32:364–72.
40. Sabbagh P, Mohammadnia-Afrouzi M, Javanian M, et al. Diagnostic methods for Helicobacter pylori infection: Ideals, options, and limitations. Eur J Clin Microbiol Infect Dis 2019;38:55–66.
41. Patel SK, Pratap CB, Verma AK, et al. Pseudomonas fluorescens-like bacteria from the stomach: A microbiological and molecular study. World J Gastroenterol 2013;19:1056–67.
© 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology